This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Thu, 12/05/2024 - 11:59 Dec. 4, 2024 – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 million. As we’ve seen with their recent Medicare and CPT I code approvals, this technology is both valuable and ready today in the fight against heart disease.”
In 2024, the FDA approved Flyrcado for patients with known or suspected coronary artery disease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. Dorbala, S., Di Carli,M. Bateman, T.
The ACC 2024 meeting is now complete, after over 17,000 cardiology professionals converged in Atlanta to witness cardiovascular medicine evolve in front of their eyes. The post Cardiac Wire’s Top 8 Takeaways from ACC 2024 appeared first on Cardiac Wire.
milla1cf Wed, 03/20/2024 - 18:50 March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve below-the-knee resorbable magnesium scaffold (BTK RMS). For more information: www.biotronik.com References: 1 Kwong M.,
vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible. This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment. 2024,November 8).
With the rise of digital health, innovative solutions are emerging that can significantly impact patient care and recovery while simultaneously addressing health equity. In 2020, she received the AHA/ASA David Sherman award for her lifetime contributions to post acute stroke care, research, training, innovation, and advocacy ([link] ).
2024, [link]. Longitudinal assessment of safety of FEMOROPOPLITEAL endovascular treatment with paclitaxel-coated devices among Medicare beneficiaries.” Journal of Vascular Surgery Cases, Innovations and Techniques, vol. For more information: www.heartflow.com References 1 Krievins, Dainis K., Journal of Vascular Surgery, Mar.
Image courtesy: Getty Images christine.book Tue, 06/18/2024 - 11:07 June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. Presented at EuroPCR 2024. JACC 2020. 5 Saito S, et al.
In late 2023, CMS released the 2024Medicare Physician Fee Schedule (MPFS) Final Rule, ushering in key policy changes for the Quality Payment Program (QPP). The 2024 payment adjustment is important to compensation for Medicaid services provided. Be sure to check your qualifying status using the QPP Participation Status Tool.
With the recent changes to MIPS reporting requirements, healthcare providers seek innovative solutions to streamline their reporting processes while maximizing incentives and improving patient care. Additionally, the 2024 final rule retains the methodology for measuring scores and achieving points with no notable alterations.
These findings challenge the long-held assumption that frequent symptoms justify short-duration monitoring, said Mintu Turakhia, MD, iRhythm Chief Medical and Scientific Officer and EVP of Product Innovation. Accessed April 25, 2024. iRhythm Technologies, 2024. Treasure Island (FL): StatPearls Publishing; June 5, 2023.
milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer.
The launch of the Duo Venous Stent System represents another step forward in achieving our aspiration to innovate interventional procedures with advanced medical technology,” said Heather Hudnut Page, Vice President and Business Leader of Peripheral Vascular at Philips. “In J Vasc Surg Venous Lymphat Disord. 2017;5:678-687. [5]
HIMSS 2024 will be held March 11-15 in Orlando, FL. He has 15 years’ experience with e-government development, but has found his heart is in digital health and innovation. These sessions will be offered throughout the conference week, according to HIMSS24 program planners.
As a whole, the computed tomography market size in the US in 2024 is estimated to be $2.38 billion by 2029, growing at a CAGR of 5.86% in the forecast period (2024-2029), according to a new report released by Mordor Intelligence. billion, and expected to reach $3.18 Halpern, MD, and Vijay M. Technology advancements.
milla1cf Wed, 01/03/2024 - 11:45 January 3, 2024 — HeartFlow, Inc. , 3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. This accomplishment is a testament to HeartFlow's dedication to driving a new standard of care and marks an important milestone for the company.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. TCT 2024 4 WHO.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content